2024-04-29

(1) 2023 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2023 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2023 ANNUAL REPORT; (4) 2023 FINAL FINANCIAL REPORT AND 2024 FINANCIAL BUDGET REPORT; (5) 2023 PROFIT DISTRIBUTION PLAN; (6) APPOINTMENT OF EXECUTIVE DI

2024-04-26

Annual Report 2023

2024-04-17

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR THE PHASE III CLINICAL TRIAL PROTOCOL OF IMM01 (TIMDARPACEPT)

2024-04-08

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024

2024-03-25

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023

2024-03-13

DATE OF BOARD MEETING

2024-03-06

VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS

2024-03-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 29 February 2024

2024-03-04

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

2024-03-01

(1) RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF FINANCIAL OFFICER AND AUTHORIZED REPRESENTATIVE; (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR; AND (3) APPOINTMENT OF AUTHORIZED REPRESENTATIVE

2024-02-20

Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

2024-02-20

Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

2024-02-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2024

2024-01-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2023

2023-12-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2023

2023-11-20

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF IMM2510 FOR THE TREATMENT OF ASPS

2023-11-08

VOLUNTARY ANNOUNCEMENT - ORPHAN-DRUG DESIGNATION FROM FDA IN RESPECT OF COMBINATION OF IMM01 AND AZACITIDINE FOR THE TREATMENT OF CMML

2023-11-07

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE II CLINICAL TRIAL OF IMM2510

2023-11-06

VOLUNTARY ANNOUNCEMENT - PRESENTATIONS OF PHASE II RESEARCH STUDIES OF IMM01 AT THE 2023 ASH ANNUAL MEETING

2023-11-03

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2023